StockNews.com Begins Coverage on Cyclacel Pharmaceuticals (NASDAQ:CYCC)
Source: Americanbankingnews
Research analysts at StockNews.com began coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC – Get Free Report) in a note issued to investors on Thursday. The brokerage set a “sell” rating on the biotechnology company’s stock. Cyclacel Pharmaceuticals Stock Performance Shares of NASDAQ:CYCC opened at $1.05 on Thursday. The company has a market cap of $2.07 […]